Encyclopedia of Nanotechnology

Living Edition
| Editors: Bharat Bhushan

Nanotechnology in Cardiovascular Diseases

Living reference work entry
DOI: https://doi.org/10.1007/978-94-007-6178-0_336-2

Definition

Nanomolecular imaging is a new type of imaging with a combination of nanomaterial and molecular biology, using nanoparticles to visualize, characterize, and measure biological processes at molecular and cellular levels in living systems, including radiotracer imaging/nuclear medicine, magnetic resonance (MR) imaging, MR spectroscopy, optical imaging, ultrasound, and other nanomolecular imaging.

Overview

Recently, the emergence of nanomolecular imaging has set the stage for an evolutionary leap in the diagnosis and therapeutics of diseases such as cancer and neurological and cardiovascular diseases (CVDs) [1, 2, 3]. CVD is the leading cause of morbidity and mortality in the world. The pathology underpinning CVD is chronic inflammation involving the injury of arterial wall, the infiltration of leukocytes, and the remodeling of vasculature. The main benefits of nanomolecular imaging are derived from the combination of cell type-specific molecular-based, molecular-molecular...

Keywords

Atherosclerotic Plaque Vulnerable Plaque Magnetic Resonance Spectroscopic Imaging Intraplaque Hemorrhage Plaque Disruption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Ferrari, M.: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161–171 (2005)CrossRefGoogle Scholar
  2. 2.
    Bhaskar, S., et al.: Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part. Fibre Toxicol. 7, 3 (2010)CrossRefGoogle Scholar
  3. 3.
    Yang, X.: Nano- and microparticle-based imaging of cardiovascular interventions: overview. Radiology 243, 340–347 (2007)CrossRefGoogle Scholar
  4. 4.
    Wickline, S.A., Neubauer, A.M., Winter, P., Caruthers, S., Lanza, G.: Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler. Thromb. Vasc. Biol. 26, 435–441 (2006)CrossRefGoogle Scholar
  5. 5.
    Godin, B., et al.: Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol. Sci. 31, 199–205 (2010)CrossRefGoogle Scholar
  6. 6.
    Douma, K., et al.: Nanoparticles for optical molecular imaging of atherosclerosis. Small 5, 544–557 (2009)CrossRefGoogle Scholar
  7. 7.
    Stinaff, E.A., et al.: Optical signatures of coupled quantum dots. Science 311, 636–639 (2006)CrossRefGoogle Scholar
  8. 8.
    Anderson, D.R., Tsutsui, J.M., Xie, F., Radio, S.J., Porter, T.R.: The role of complement in the adherence of microbubbles to dysfunctional arterial endothelium and atherosclerotic plaque. Cardiovasc. Res. 73, 597–606 (2007)CrossRefGoogle Scholar
  9. 9.
    Tabas, I.: Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36–46 (2010)CrossRefGoogle Scholar
  10. 10.
    Sitia, S., et al.: From endothelial dysfunction to atherosclerosis. Autoimmun. Rev. 9, 830–834 (2010)CrossRefGoogle Scholar
  11. 11.
    Nahrendorf, M., et al.: Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114, 1504–1511 (2006)CrossRefGoogle Scholar
  12. 12.
    Lipinski, M.J., et al.: Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc. Imaging 2, 637–647 (2009)CrossRefGoogle Scholar
  13. 13.
    McCarthy, J.R., Korngold, E., Weissleder, R., Jaffer, F.A.: A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 6, 2041–2049 (2010)CrossRefGoogle Scholar
  14. 14.
    Stephen, S.L., et al.: Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. Int J Hypertens. 2010, 646929 (2010)CrossRefGoogle Scholar
  15. 15.
    Farmer, D.G., Kennedy, S.: RAGE, vascular tone and vascular disease. Pharmacol. Ther. 124, 185–194 (2009)CrossRefGoogle Scholar
  16. 16.
    Oka, H., et al.: Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway. Arterioscler. Thromb. Vasc. Biol. 20, 244–250 (2000)CrossRefGoogle Scholar
  17. 17.
    White, S.J., Sala-Newby, G.B., Newby, A.C.: Overexpression of scavenger receptor LOX-1 in endothelial cells promotes atherogenesis in the ApoE(−/−) mouse model. Cardiovasc. Pathol. 6, 369–373 (2011)Google Scholar
  18. 18.
    Flacke, S., et al.: Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104, 1280–1285 (2001)CrossRefGoogle Scholar
  19. 19.
    Winter, P.M., et al.: Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2103–2109 (2006)CrossRefGoogle Scholar
  20. 20.
    Stone, V., Donaldson, K.: Nanotoxicology: signs of stress. Nat. Nanotechnol. 1, 23–24 (2006)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.The Key Laboratory of Remodeling-related Cardiovascular Diseases, Ministry of EducationCapital Medical UniversityBeijingChina
  2. 2.Beijing Institute of Heart Lung and Blood Vessel DiseasesBeijing Anzhen HospitalBeijingChina